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Despite its key role in the molecular pathology of Alzheimer’s disease (AD), the
physiological function of amyloid precursor protein (APP) is unknown. Increasing
evidence, however, points towards a neuroprotective role of this membrane protein
in situations of metabolic stress. A key observation is the up-regulation of APP following
acute (stroke, cardiac arrest) or chronic (cerebrovascular disease) hypoxic-ischemic
conditions. While this mechanism may increase the risk or severity of AD, APP by itself or
its soluble extracellular fragment APPsα can promote neuronal survival. Indeed, different
animal models of acute hypoxia-ischemia, traumatic brain injury (TBI) and excitotoxicity
have revealed protective effects of APP or APPsα. The underlying mechanisms involve
APP-mediated regulation of calcium homeostasis via NMDA receptors (NMDAR),
voltage-gated calcium channels (VGCC) or internal calcium stores. In addition, APP
affects the expression of survival- or apoptosis-related genes as well as neurotrophic
factors. In this review, we summarize the current understanding of the neuroprotective
role of APP and APPsα and possible implications for future research and new therapeutic
strategies.
Keywords: Alzheimer, ischemia, calcium toxicity, cell death, amyloid precursor protein, stroke, traumatic brain
injury, neuroprotection
INTRODUCTION
Amyloid precursor protein (APP) has been first described in 1987 as a potential substrate of
pathological deposits in the nervous system (Kang et al., 1987). By now, there is good evidence from
multiple lines of research that specific domains of APP do indeed contribute to amyloid plaques as
found in patients with Alzheimer’s disease (AD; Hardy and Selkoe, 2002). On the other hand, the
function of this ubiquitously expressed protein in healthy brains remains poorly understood. Recent
evidence from neurological patients and from different disease models hint towards a potential
neuroprotective function of APP under conditions of acute cellular insult: APP is up-regulated
following hypoxia, ischemia or traumatic brain injury (TBI; Van den Heuvel et al., 1999; Pottier
et al., 2012). This reaction coincides well with some known interactions between APP and other
proteins which are relevant for homeostatic regulation of cell integrity under stressful conditions,
such as certain glutamate receptors, calcium channels or gene-regulatory networks (Russo et al.,
2005). With respect to the underlying molecular mechanisms it is important to note that the integral
membrane protein APP can give rise to both, protective and potentially damaging molecules
following cleavage by different secretases (Brunholz et al., 2012). These cleavage processes keep a
balance between different amyloidogenic and non-amyloidogenic products of APP, including the
protective APPsα fragment which is secreted into the extracellular space (Mattson et al., 1993a).
Together, APP or its fragments may well have a neuroprotective role during acute challenges of
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neuronal integrity, and it may exert this function by regulating
neuronal calcium homeostasis and cell survival. Novel findings
on APP-related neuroprotective mechanisms open promising
new therapeutic strategies in stroke, AD and TBI.
In the present review article, we summarize the evidence for a
neuroprotective function of APP in the adult brain. After a brief
introduction of the protein and its metabolites, we summarize
current knowledge from clinical, animal and in vitro studies
about its role in stroke, brain injury and neurodegeneration.
Finally, we discuss possible mechanisms and point out several
promising therapeutic targets.
APP STRUCTURE, EXPRESSION,
TRAFFICKING, CLEAVAGE AND
SUBCELLULAR LOCALIZATION
APP is a type-1 transmembrane protein comprising a long
extracellular N-terminal domain, a transmembrane region and
an intracellular C-terminal domain, APP intracellular domain
(AICD; Kang et al., 1987). Alternative splicing of the APP
gene, which is located on chromosome 21, produces three
isoforms containing 695, 751 and 770 amino acids, respectively
(Beyreuther et al., 1993). While APP751 and APP770 are
expressed almost ubiquitously, APP695 can be found nearly
exclusively in neurons. Depending on the isoform, the APP
extracellular domain consists of up to six different subdomains
with specific structural motives and various binding partners
such as extracellular matrix proteins (heparine, collagene,
laminine, proteoglycans), metals (copper, zinc) and regulatory
proteins (LDL-receptor-related protein, F-spondin; Gralle and
Ferreira, 2007; Müller and Zheng, 2012). After translation
in the endoplasmic reticulum (ER), APP undergoes various
post-translational modifications in the Golgi complex before
it is transported to the cell membrane (Caporaso et al.,
1994). The mature membrane protein can be processed by
different membrane-associated proteolytic enzymes, beginning
with cleavage of the transmembrane domain by γ-secretase.
Subsequent cleavage by α-secretase results in three fragments:
AICD, a short p3 fragment and the secreted soluble APP α
(APPsα). Alternatively, cleavage by the β-secretase BACE-1
(Beta-site APP Cleaving Enzyme 1) releases APPsβ and the
neurotoxic amyloid β (Aβ) peptide (refer to Haass et al., 2012 for
review on processing of APP). Under normal conditions, only a
small fraction of the expressed APP is secreted, and cleavage by
α-secretases outweighs the amyloidogenic pathway by far (Hick
et al., 2015).
In neurons, APP is found in somatodendritic and axonal
compartments as well as in the presynaptic active zone (Laßek
et al., 2016) which it reaches by fast axonal transport (Brunholz
et al., 2012). Its intracellular trafficking involves four different
neuronal trafficking adaptors including Mint1 and is regulated
by tyrosine phosphorylation (Dunning et al., 2016). Expression,
trafficking and processing of APP are complexly regulated,
including prominent changes during pathological states. APP
expression is upregulated under conditions of metabolic stress
(Hoyer et al., 2005), ischemia (Pottier et al., 2012), brain injury
(Van den Heuvel et al., 1999) and inflammation (Herbst-
Robinson et al., 2015). APP processing and degradation differ
under conditions of acute stress. In response to increased levels
of intracellular calcium, APP is degraded via the ubiquitin-
proteasome proteolytic pathway (Jung et al., 2015). Facilitated
degradation might counteract overexpression of APP under
conditions of acute stress, prevent accumulation of misfolded
protein and its processing into Aß. As an additional adaptive
mechanism, cleavage of the protein is regulated by synaptic
activity, affecting the balance between amyloidogenic and
non-amyloidogenic pathways (Kamenetz et al., 2003; Cirrito
et al., 2005). Intriguingly, APP is expressed and cleaved
heterogeneously in different types of neurons and in astrocytes
and in different brain areas, which might contribute to variable
susceptibility to insults between brain regions and cell types
(Del Turco et al., 2016; Liao et al., 2016). Activated by
proinflammatory cytokines, astrocytes were shown both to
contribute to Aß production as well as to stimulate the
secretion of APPsα, suggesting a significant contribution of
glia cells to production and cleavage of APP and a tight
coupling between APP processing and the immune system
(Zhao et al., 2011; Yang et al., 2015). While still quite
superficially understood, this activity- and stress-dependent
multi-level relation of APP in neural, glial and immune cell
response strongly suggests a role as an acute phase protein with
functions in cellular survival under metabolically challenging
conditions.
FUNCTIONS OF APP AND ITS
METABOLITES
APP is highly conserved across different phyla including
mammals, insects and nematodes, suggesting that the protein
has advantageous effects on survival and reproduction of animals
(Müller and Zheng, 2012; van der Kant and Goldstein, 2015).
Indeed, in the nematode C. elegans knock-out of APP-like
protein (APL-1) is lethal (Hornsten et al., 2007). Drosophila
lacking the APP ortholog APPL exhibit severe memory deficits
(Bourdet et al., 2015). Most knowledge on systemic functions
of APP has been gained from studies of genetically modified
rodents. Remarkably, mice lacking APP are viable, fertile, and
exhibit a relatively mild phenotype. Alterations include reduced
body and brain weight and several neurological symptoms like
reduced grip strength (Weyer et al., 2011; Caldwell et al.,
2013), deficits in spatial memory (Puzzo et al., 2011), and
increased susceptibility to seizures (Steinbach et al., 1998).
This phenotype may be related to changes at the cellular and
network level like reduced numbers of dendritic spines, reduced
hippocampal LTP and altered short-term plasticity (Seabrook
et al., 1999; Weyer et al., 2011; Jedlicka et al., 2012; Korte et al.,
2012). The absence of more severe deficits is likely due to the
existence of homologous proteins, called APLP1 and APLP2,
which can compensate the lack of APP due to overlapping
functions (Aydin et al., 2012). Indeed, double knockout mice
lacking two of the three homologous proteins are much more
heavily affected: mice lacking APP and the globally expressed
APLP2 as well as APLP1-KO/APLP2-KO mice die perinatally
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due to impaired neuromuscular transmission (Wang et al.,
2005), while mice deficient for APP and APLP1, which is
predominantly expressed in the brain, survive birth but exhibit
rather severe deficits (Heber et al., 2000). Triple knock-out mice
die during embryonic development or shortly after birth and
show lissencephaly-like cortical malformations (Herms et al.,
2004), pointing towards a role for APP and its homologs in
essential developmental mechanisms like neuronal migration,
neurite outgrowth and synaptogenesis. Detailed studies at the
cellular and molecular level revealed several further functions
of APP. The protein is involved in regulation of synaptic
vesicle exocytosis (Kohli et al., 2012) glutamatergic, GABAergic
and cholinergic synaptic transmission (Wang et al., 2005,
2014; Schrenk-Siemens et al., 2008) and synapse formation
(Priller et al., 2006). Interestingly, it also regulates endosomal
phosphoinositide metabolism and prevents neurodegeneration
(Balklava et al., 2015), and it interacts with a large variety
of survival-related cascades (Russo et al., 2005; Venezia et al.,
2007).
APPsα and APPsβ
Several functions of APP seem to be mediated by its
soluble cleavage product APPsα. Selective expression of APPsα
in mice with APP−/− background abolishes most of their
deficits, rescuing LTP as well as the typical anatomical and
behavioral abnormalities (Ring et al., 2007; Hick et al.,
2015). Mice selectively expressing APPsα on APP-KO/APLP2-
KO background (which by itself is lethal) survive well into
adulthood and show only a mildly altered phenotype, similar
to simple APP-KO animals (Zhang et al., 2013). Enhancing
APPsα levels by over-expression of ADAM-10 increases cortical
synaptogenesis in vivo (Bell et al., 2008). Intraventricular
application of APPsα enhances memory in mice (Meziane
et al., 1998). Altogether, there is strong evidence that APPsα
mediates many of the effects of APP on brain development
and supports several cognitive functions. In addition, the
APPsα fragment has been shown to mediate a variety of
neuroprotective and trophic effects (Hick et al., 2015; Fol et al.,
2016; Hefter et al., 2016; Plummer et al., 2016), as discussed
in following sections. It is important to note that secretion
of APPsα is regulated by neuronal activity (Kirazov et al.,
1997; Gakhar-Koppole et al., 2008) and by activated astrocytes
(Yang et al., 2015). This may point towards state-dependent
functions of the protein, in line with the neuroprotective
effects described below. The trophic effects of APPsα are dose-
dependent, beginning as low as 100 pM, reaching an optimum
at 10 nM and decreasing at higher doses (Demars et al.,
2011).
Notably, APPsβ fails to mimic the beneficial effects of
APPsα, although there is only a difference of 16 amino acids
between both proteins (Hick et al., 2015). In other studies,
however, trophic effects of APPsβ were detected, albeit less
potent than those of APPsα (Chasseigneaux et al., 2011).
Interestingly, APPsβ was found to undergo further proteolytic
cleavage and bind to ‘‘death receptor 6’’, activating caspase-6
and thus contributing to neurodegeneration (Nikolaev et al.,
2009).
APP Intracellular Domain (AICD)
The intracellular domain of APP, termed AICD, interacts with
various cytosolic signaling cascades including glycogen synthase
kinase 3 (GSK-3), Ras proteins and MAPK pathways and is
able to translocate to the nucleus after forming a complex with
the adaptor protein Fe65 (Schettini et al., 2010). There, it is
involved in regulation of genes associated with survival and
apoptosis (Müller et al., 2008; Multhaup et al., 2015). Indeed,
overexpression of AICD was found to induce apoptosis by
interaction with the p53-pathway (Ozaki et al., 2006; Nakayama
et al., 2008). Moreover, AICD modulates intracellular calcium
homeostasis and ATP content (Hamid et al., 2007) and affects
synaptic plasticity and hippocampus-dependent learning by
increasing LTP (Klevanski et al., 2015).
Amyloid ß
Resulting from APP cleavage by BACE-1, Aβ peptides can
accumulate extracellularly as soluble oligomers or in amyloid
plaques, promoting neurodegeneration in AD (Haass, 2010).
Interestingly, Aβ can be internalized by neurons and accumulates
in the cytosol as well as within endosomes/lysosomes and
mitochondria (Chen and Yan, 2006). It exerts neurotoxic effects
via a variety of mechanisms, such as disruption of calcium
homeostasis (Berridge, 2010), overactivation of mGluR5 (Zhang
et al., 2015), impairment of synaptic transmission, plasticity and
network function (Kamenetz et al., 2003; Palop and Mucke,
2010), mitochondrial dysfunction (Chen and Zhong, 2013) and
apoptosis (Umeda et al., 2011). Remarkably, it is also able to
translocate into the nucleus and influence apoptosis-related gene
transcription (Barucker et al., 2014; Multhaup et al., 2015). The
APP fragment has also been suggested to form channel-like pores
in neuronal membranes, but the underlying mechanisms are
currently unknown (Barucker et al., 2014).
LINKS BETWEEN ISCHEMIA, BRAIN
INJURY AND
NEURODEGENERATION—RESULTS FROM
HUMAN STUDIES
Sporadic AD is the most common cause of dementia and
constitutes one of the most imminent medical problems in
developed countries (Prince et al., 2015). Cognitive deficits
in AD are caused by progressive loss of neurons, beginning
in the temporal lobe and resulting in severe global brain
atrophy (Fox and Schott, 2004). The neuronal loss is linked
to pathological accumulation of amyloid and tau protein, as
first described by Alzheimer (1906). No causal treatments
exist at this stage of the disease. However, irreversible
macroscopic pathology and cognitive decline are preceded by
functional deficits such as disturbance of cellular calcium- and
energy-homeostasis (Mattson, 1994), mitochondrial dysfunction
(Swerdlow and Khan, 2004; Rönnbäck et al., 2016), synaptic
failure (Selkoe, 2002) and activation of pro-apoptotic pathways
(Mattson, 2000), offering an opportunity for detection and
intervention at the preclinical stage (Jack and Holtzman, 2013).
Interestingly, various lines of evidence suggest that molecular
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pathomechanisms in AD such as amyloid deposition and
disrupted calcium homeostasis overlap with those in hypoxia-
ischemia (Peers et al., 2009) and TBI (Magnoni and Brody,
2010).
In many pathologies of the CNS such as TBI and stroke
the brain-blood barrier (BBB) is disturbed which results in
extravasation of blood-derived proteins including albumin and
inflammatory mediators into the brain tissue (Zhao et al.,
2015). Presence of albumin in the extracellular space may
act epileptogenic and promote degeneration (Friedman et al.,
2009). Inflammatory cytokines may regulate secretase activity
and both facilitate non-amyloidogenic cleavage as well as Aß
deposition (Zhao et al., 2011; Yang et al., 2015), possibly
contributing to the development of AD later on (Sastre et al.,
2008). Alternatively, amyloid may directly diffuse from vessels
into the brain tissue through a malfunctioning BBB (Pluta et al.,
2009). Amyloid plaques, in turn, are well known to evoke a strong
inflammatory response with activation of microglia, astrocytes
and inflammatory mediators.
Amyloid accumulates and deposits into plaques if its
intracellular degradation and extracellular clearance are
disturbed. Proteolytic degradation is inhibited by lack of energy
substrates and oxidative stress, while extracellular degradation
requires intact interstitial and cerebrospinal fluid flow and BBB
function and is impaired in inflammation (Iliff et al., 2015;
Tarasoff-Conway et al., 2015). As these processes are disturbed
in stroke and TBI, both conditions may lead to impaired amyloid
clearance and AD development.
In line with these pathomechanisms, a history of TBI
(Fleminger et al., 2003; Sivanandam and Thakur, 2012), stroke
(Thiel et al., 2014) and cardiac arrest (de la Torre, 2006) are
risk factors for developing AD. Below, we will describe the
similarities between these conditions in detail. Figure 1 shows
the pathophysiological cascades leading from acute insult to
long-term neurodegeneration.
TRAUMATIC BRAIN INJURY, APP AND AD
TBI Leads to Amyloid Pathology and
Strongly Increases the Risk for AD and
Cognitive Decline
TBI is a debilitating and life-threatening condition which is the
leading cause of disability in people under 35 years in industrial
countries (Feigin et al., 2013). Besides acute primary damage,
TBI promotes secondary neurodegeneration and increases the
risk for developing AD by ∼2-fold (Mortimer et al., 1991;
Mayeux et al., 1993; Schofield et al., 1997; Guo et al., 2000;
Fleminger et al., 2003). Following TBI, diffuse Aβ deposits
can be found in the temporal cortex as early as 2 h after the
insult (Ikonomovic et al., 2004). Furthermore, post mortem
histological analysis shows that deposition of amyloid ß-protein
in the brain occurs in approximately one-third of individuals
who die shortly after a severe head injury (Roberts et al.,
1994). Aβ levels are altered in cerebro-spinal and interstitial
cerebral fluid in patients with TBI (Magnoni and Brody, 2010;
Tsitsopoulos and Marklund, 2013) and correlate with clinical
outcome (Magnoni and Brody, 2010). A history of TBI prior to
the onset of dementia correlates with greater amyloid burden
in patients with mild cognitive deficits (Mielke et al., 2014)
and is associated with faster rates of cognitive decline in
AD patients (Moretti et al., 2012; Gilbert et al., 2014). In
TBI patients, APP transcription is upregulated and its axonal
transport is interrupted due to diffuse axonal injury, which
results in deposition of APP and its products in axonal ‘‘bulbs’’
(Hayashi et al., 2015). These results from human studies are
in line with a large body of evidence from various models
of TBI in mice, rats and sheep, where APP overexpression
following TBI has been extensively studied. In models of focal
cerebral injury inflicted by stabbing or weight drop local APP
immunoreactivity increased in neurons as well as in astrocytes
(Otsuka et al., 1991; Lewén et al., 1995, 1996). In the midline
fluid percussion model of diffuse brain injury in adult rats APP
expression was globally elevated in cortex and hippocampus
within hours following the insult (Murakami et al., 1998); in a
lateral fluid percussion model APP was overexpressed as early
as 1 h after the insult (Pierce et al., 1996). In a weight fall
model of brainstem injury in adult rats APP mRNA levels rose
as soon as 1 h post-impact, peaked 3 h after the injury at almost
twofold baseline level and declined to baseline within 24 h (Yang
et al., 2014). Similarly, in an ovine TBI model APP mRNA was
up-regulated as soon as 30 min post-impact (Van den Heuvel
et al., 1999).
Protective Function of APP and
APPsα in TBI
While over-expression of APP following mechanical insults
has been observed several decades ago, the functional effects
remained unclear until recently. By now, evidence from different
animal models points towards an acute neuroprotective effect
of APP and APPsα in TBI (Plummer et al., 2016). In
diffuse traumatic injury in rats, intraventricular administration
of APPsα 30 min after the insult reduced axonal injury
and apoptosis and improved motor and cognitive outcome
(Thornton et al., 2006). In the same model of TBI, mice lacking
APP suffered from greater cognitive and motor impairment in
correspondence with larger lesions and increased hippocampal
cell loss as compared to WT, again suggesting a protective
role of APP in TBI (Corrigan et al., 2012a). Once again,
posttraumatic application of exogenous APPsα mitigated these
deficits (Corrigan et al., 2012b). These protective effects were
found to be mediated by the heparin-binding D1 and D6a
domains of APPsα (Corrigan et al., 2011). In an additional
study conducted by the same group, the neuroprotective site was
pinned down to the APP96-110 sequence in D1, which, applied
intraventricularly post-trauma, was enough to significantly
improve histological and functional outcome (Corrigan et al.,
2014).
At first glance, these findings seem to contradict exacerbation
of amyloid pathology and increased risk of AD following TBI.
However, there are several possibilities how the two mechanisms
may be reconciled. First, APPsα may exert neuroprotective
functions independent from the detrimental effects of Aß or
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FIGURE 1 | Pathophysiological changes in neurons following acute ischemic and traumatic insults. Micro- and macroscopic focal strokes, global
hypoxia-ischemia and traumatic brain injury (TBI) lead to abruption of extracellular glucose and oxygen supply and excessive glutamate release. One major shared
pathomechanism is NMDAR-mediated excitotoxicity, or over-activation of NMDAR by glutamate, which facilitates sodium and calcium influx. Due to excessive ion
influx, the cellular membrane potential is depolarized, which leads to activation of voltage gated calcium channels such as LTCC, initiating a vicious cycle of ion influx,
calcium overload, depolarization and aberrant activity. Successively calcium from intracellular calcium stores, particularly mitochondria and the ER, is released,
increasing calcium levels to up to 200-fold of ∼100 nM during resting. Calcium activates secondary messengers that are able to translocate to the nucleus and
modulate gene transcription. Long-lasting or severely elevated calcium levels may lead to activation of caspases and apoptosis. Following the osmotic gradient,
water enters the cell and leads to cell swelling and brain edema. Due to glucose and oxygen shortage and excessive formation of reactive oxygen species (ROS),
mitochondrial function is compromised and ATP production halts. Malfunction of the energy demanding ion pumps, predominantly the sodium potassium pump,
ultimately leads to breakdown of the membrane potential, a phenomenon known as anoxic or hypoxic spreading depolarization or spreading depression (due to
depression of network activity in the field potential recording). Given the energy supply is timely restored, this stage can be reversed without long-lasting
morphological damage. If the insult is protracted, neurons might undergo (dependent of insult’s severity) necrotic or apoptotic death or degenerate with a delay of
days to decades due to synaptic or metabolic malfunction. Acute cell death and delayed degeneration contribute to brain atrophy and development of dementia.
Glu, glutamate; Gluc, glucose; LTCC, L-Type calcium channel; NMDAR, NMDA receptor; AMPAR, AMPA receptor; M, mitochondrion; NCL, nucleus;
ER, endoplasmic reticulum; ROS, reactive oxygen species.
amyloid plaques. Second, APPsα could prevent deposition of
Aß and further growth of plaques. Third, APPsα may promote
clearance of plaques. There is evidence for all three mechanisms.
APPsα was shown to modulate BACE activity, possibly
inhibiting amyloidogenic cleavage (Obregon et al., 2012). As
described in sections ‘‘APPsα and APPsβ’’ and ‘‘Mechanisms
of Neuroprotection by APP and APPsα Protection in Hypoxia-
Ischemia, Excitotoxicity, Degeneration’’, APPsα counteracts Aß-
mediated excitotoxic damage and delayed degeneration by
various trophic and regulatory effects on calcium homeostasis,
synaptic function and survival pathways. Recently Fol et al.
(2016) discovered that APPsα can ameliorate amyloid pathology
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by recruitment of microglia, underlining its involvement in
clearance of amyloid.
BRAIN ISCHEMIA, APP AND AD
Over-Expression, Amyloidogenic
Processing of APP and Increased
Risk of AD
Cardiovascular diseases and ischemic stroke share overlapping
genetic and metabolic risk factors such as hypertension,
dyslipidemia, glucose intolerance or diabetes and adipositas
(Arboix, 2015). Recently these risk factors were established
to also increase the odds of developing AD (Orehek, 2012;
Wiesmann et al., 2013; Traylor et al., 2016). Moreover, hypoxic-
ischemic conditions of the brain such as in ischemic stroke
(Honig et al., 2003), heart arrest (de la Torre, 2006), and cerebral
small vessel disease (Cai et al., 2015) directly correlate with
AD risk, suggesting that cerebrovascular dysfunction is one
possible cause of the neurodegenerative disease (Humpel, 2011;
Orehek, 2012). Data from a large meta-analysis (Zhou et al.,
2015) and a longitudinal study with over 6500 participants
(Tosto et al., 2016) show that ischemic stroke increases AD
risk by about 1.6 to 2.2-fold, respectively. Several studies
indicate that, vice versa, AD patients have an increased risk
to develop ischemic (Chi et al., 2013) and hemorrhagic (Chi
et al., 2013; Tolppanen et al., 2013; Zhou et al., 2015)
stroke and have a higher prevalence of cerebrovascular lesions
(Jellinger, 2010). Other studies, however, did not find an
increased risk of ischemic stroke in patients with AD (Imfeld
et al., 2013; Tolppanen et al., 2013; Zhou et al., 2015).
Not surprisingly, cerebrovascular disease and AD contribute
additively to cognitive impairment in patients (Hohman et al.,
2015) and mouse models (Pimentel-Coelho et al., 2013), possibly
forming a vicious cycle of ischemia and neurodegeneration (Pluta
et al., 2013).
It has been suggested that cerebrovascular disease, vascular
dementia and AD share common pathophysiological cascades
such as altered APP processing (Selnes et al., 2010), perturbed
energy metabolism (Chen and Zhong, 2013) and pathological
immune response (Brod, 2000). These common pathways may
then result in overlapping histopathological findings (de la Torre,
2002; Pluta et al., 2009, 2012; Attems and Jellinger, 2014).
APP overexpression and Aβ deposition likely play a pivotal
role in these processes. In ischemic stroke patients, expression
of APP is indeed increased (Pottier et al., 2012) and serum
Aβ levels are elevated, correlating with infarct size and clinical
outcome (Lee et al., 2005). Likewise, patients who suffered from
hypoxia during a cardiac arrest present with increased Aβ levels,
which—again—correlate with clinical outcome (Zetterberg et al.,
2011). Increased age-related deposition of Aβ was also shown
in chronic cerebral vascular disease in rats (Schreiber et al.,
2014). However, elevation of Aβ following ischemia is transient.
A recent study employing Pittsburgh Compound-B positron
emission tomography (11C-PiB-PET; an in vivo imaging method
of amyloid), revealed no accumulation of Aβ in patients
18 months after ischemic stroke (Sahathevan et al., 2016).
Neuroprotective Role of APP in Ischemia in
Animal Studies
At the first glance, findings concerning APP in conditions of
hypoxia/ischemia seem to be contradictory. On the one hand,
the pathological role of APP is supported by multiple animal
studies. On the other hand, several studies show beneficial effects
of APP in animal models of hypoxia-ischemia. It can be assumed
that these opposing effects are mediated by the different cleavage
products of APP.
On the one hand, ischemia and oxidative stress enhance
BACE-1 and γ-secretase activity, resulting in increased Aβ
deposition in rats and mice (Sun et al., 2006; Guglielmotto, 2009;
Li et al., 2009). APP accumulates in regions of neurodegeneration
following focal cerebral ischemia in the rat (Stephenson et al.,
1992). Stroke in rats with Aβ pathology leads to aggravated
comorbidity, hippocampal atrophy, and cognitive impairment,
similar to the consequences of stroke in AD patients (Amtul et al.,
2014).
On the other hand, postischemic intraventricular application
of APPsα increases neuronal survival in a model of transient focal
ischemia in rats (Smith-Swintosky et al., 1994). APP-KO as well
as BACE-KO mice are unable to maintain cerebral blood flow
and experience drastically increased acute mortality in a model of
global cerebral ischemia (Koike et al., 2012). Overexpression of
APP provides neuroprotection following middle cerebral artery
occlusion in rats (Clarke et al., 2007). There is compelling
evidence that APP acts as a potent anti-thrombotic agent (Van
Nostrand, 2016). Moreover, it is required for effective immune
and glial cell responses to inflammatory stimuli (Carrano
and Das, 2015). With glutamate excitotoxicity being a key
pathomechanism of ischemic neuronal damage (Broughton et al.,
2009), activation of ADAM10, and thus facilitation of APPsα
production, provides neuroprotection against excitotoxic stress
in vivo (Clement et al., 2008). These findings are in line with
models of AD where expression of APPsα protects against
neurodegeneration and rescues synaptic function (Fol et al.,
2016).
Taken together, these data support the importance of balance
between the beneficial APPsα and the neurotoxic amyloidogenic
pathway, thus resolving the initially contradictive results.
MECHANISMS OF NEUROPROTECTION
BY APP AND APPsα PROTECTION IN
HYPOXIA-ISCHEMIA, EXCITOTOXICITY,
DEGENERATION
As outlined in previous sections, ischemia, traumatic injury
and degeneration share some common pathological cascades
leading to neuronal death (see also Figure 1). One common
mechanism of damage is dysregulation of calcium homeostasis
(Mattson et al., 1993b; Webster et al., 2006). Intracellular
calcium levels at rest are around 100 nM, and fluctuations in
cytosolic calcium concentration are tightly coupled to metabolic
and synaptic activity (Berridge et al., 2003). Neuronal calcium
homeostasis is disturbed in AD, with strong evidence pointing
towards a pivotal role of Aβ in destabilizing the balance between
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mechanisms increasing and decreasing free intracellular calcium
(Khachaturian, 1994; LaFerla, 2002; Green and LaFerla, 2008;
Berridge, 2010). Similarly, TBI as well as ischemic-hypoxic insults
lead to drastic elevations of cellular calcium of up to 20 µM
(Yao and Haddad, 2004; Sun et al., 2008). Such acute, strong
increases, as well as longer-lasting mild perturbations of calcium
levels initiate a plethora of pathological cascades and can, finally,
activate caspases and initiate apoptosis (Mattson and Chan, 2003;
Orrenius et al., 2003).
APP and its metabolites, most of all APPsα, intervene with
these cascades on multiple levels and exert neuroprotective
effects under various conditions of cellular stress, revealing novel
possible therapeutical leverage points (Kögel et al., 2012). APPsα
was shown to mediate neuroprotection and stabilize intracellular
calcium levels in in vitro models of excitotoxicity (Mattson et al.,
1993a; Ma et al., 2009). The secreted form of APP also protects
against Aβ-mediated toxicity in rat hippocampal cell cultures
by attenuating Aβ-mediated calcium elevation (Goodman and
Mattson, 1994). In a recent study on acute hippocampal slices
(Hefter et al., 2016) we showed that APP protects neuronal
function in acute hypoxia and promotes recovery of neuronal
activity. The protective effects were largely exerted by the APPsα
fragment and mediated by inhibition of L-type calcium channels
(LTCC). These voltage-gated calcium channels (VGCC) are
beside other calcium-permeable membrane channels such as
NMDA receptors (NMDAR) and internal stores major sources
of intracellular calcium (Yao and Haddad, 2004; Thibault et al.,
2007), thus contributing to traumatic/ischemic neuronal damage
as well as to the pathophysiology underlying AD. Figure 2
summarizes major neuroprotective mechanisms of APP and
APPsα as discussed below.
Modulation of NMDA Receptors
Traumatic and ischemic injury is marked by aberrant neuronal
activity and excessive glutamate release from neurons and
glia, mediating excitotoxicity through enhanced activation of
glutamate receptors including the calcium-permeable NMDAR.
These processes form a vicious cycle of excessive cation
influx, further depolarization, opening of more channels and,
eventually, breakdown of the membrane potential, osmotic cell
swelling and death (Broughton et al., 2009; McAllister, 2011; see
also Figure 1). Application of NMDAR blockers is an established
neuroprotective strategy in models of excitotoxicity, hypoxia-
ischemia and TBI (Kubo et al., 2001) models. Remarkably,
APPsα suppresses NMDAR-mediated currents (Furukawa and
Mattson, 1998), potently attenuating calcium responses and thus
providing protection against NMDAR-mediated excitotoxicity in
hippocampal cell culture (Furukawa et al., 1996; Furukawa and
Mattson, 1998; Figure 2). Seemingly contradicting these results,
APPsα was shown to enhance LTP in acute hippocampal slices
(Ring et al., 2007) as well as in vivo, where intrahippocampal
application of the protein increased NMDAR currents, rescued
LTP and memory performance (Taylor et al., 2008). This
apparent discrepancy may be due to activation of different
NMDAR subtypes which, dependent on their subcellular
localization (synaptic vs. extrasynaptic) may promote either
synaptic potentiation or proapoptotic effects (Hardingham
FIGURE 2 | Simplified summary of proposed neuroprotective
mechanisms of amyloid precursor protein (APP) and APPsα in
response to acute stress. Expression of APP is upregulated in response to
acute metabolic insult. As depicted in Figure 1, NMDAR and LTCC are
pathologically activated, promoting excitotoxic cellular damage. Cleavage of
APP is activity-dependent and α-secretases are stimulated by NMDAR,
generating the neuroprotective APPsα fragment. APPsα acts inhibitory on
NMDAR and LTCC. This negative feedback mechanism may breach the
vicious cycle of excitotoxicity and constitute an important protective
mechanism in response to acute insults. Several further trophic, regulatory and
anti-apoptotic functions of APP and APPsα are listed. They may contribute to
acute neuroprotective effect on multiple levels. Since exact mechanisms of
interaction are oftentimes not known, this ambiguity is represented by dashed
arrows. The triple period below indicates that the list makes no claims of being
complete since many more mechanisms are being discussed.
et al., 2002; von Engelhardt et al., 2007). In our experiments
slices from wildtype mice showed postischemic potentiation
of evoked population responses whereas synaptic transmission
in slices from APP-KO mice was drastically reduced (Hefter
et al., 2016). As this kind of plasticity also depends on
NMDAR (Maggio et al., 2015), it may also be modulated by
APP.
However, we could not observe involvement of NMDAR in
APP-mediated protection from hypoxia. Taking into account
that secretion of APPsα is activity-dependent (Kirazov et al.,
1997; Gakhar-Koppole et al., 2008), its effects on NMDAR may
provide a negative-feedback loop on extrasynaptic NMDAR
in excitotoxicity or a positive feedback loop on subsynaptic
NMDAR in LTP and learning.
Modulation of L-Type Calcium Channels
LTCC belong to the family of VGCC, which are—depending
on the membrane potential—almost exclusively conductive for
calcium (Zuccotti et al., 2011). They are one of the major sources
of extracellular calcium influx in ischemia (Cataldi, 2013) and
contribute to neurodegeneration in AD when over-activated
by Aβ (Webster et al., 2006). The subtype Cav1.2 has been
identified as a potential pharmacotherapeutical target (Anekonda
and Quinn, 2011). Several studies point towards beneficial effect
of LTCC blockers in AD patients (Anekonda and Quinn, 2011;
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Lovell et al., 2015) as well as in animal models of ischemia and
neurodegeneration (Gholamipour-Badie et al., 2013). APP was
shown to interact directly with Cav1.2 in cultured hippocampal
and striatal inhibitory interneurons, with lack of APP resulting
in aberrant activity of Cav1.2 and altered short-term plasticity
(Yang et al., 2009). In primary cultures of rat cortical neurons
expression of human APP inhibited calcium oscillations by
modulation of LTCC, suggesting a pivotal role in control of
neuronal excitability (Santos et al., 2009). In line with these
results we recently found an important role of LTCC for
APP-mediated neuroprotection in hypoxia (Hefter et al., 2016).
These studies suggest that regulation of LTCC function and
thereby cytosolic calcium levels by APP may be neuroprotective.
However, the molecular mechanisms underlying regulation of
LTCC by APP, the function in healthy neurons and the role in
ischemia and degeneration remain elusive.
Effect of APP on Intracellular Calcium
Stores
Internal calcium stores, most importantly the ER and
mitochondria, play a major role in the regulation of intracellular
calcium homeostasis and contribute to elevations of calcium
levels under pathological conditions (Mattson et al., 2000).
Regulation of store-related calcium homeostasis appears to
be mediated by the intracellular domain of APP, i.e., AICD.
In cell culture studies, AICD-deficient cells show increased
cytosolic calcium concentrations, decreased ability of the ER
to buffer calcium and decreased levels of ATP (Hamid et al.,
2007). Although a direct binding of AICD to ER receptors
such as ryanodine or inositol triphosphate (IP3) receptors
has not been described, indirect effects on ER stores and on
calcium signaling in general are discussed. One such mechanism
is modulation of phosphoinositide-regulated signaling by
regulation of the PIKfyve complex, an essential kinase that
synthesizes phosphatidylinositol-3,5-bisphosphate. Its loss of
function results in neurodegeneration (Balklava et al., 2015;
Currinn and Wassmer, 2016). APP was also proposed to
modulate IP3 by affecting the transcription of GSK 3b (Hamid
et al., 2007). Moreover, AICD may affect calcium levels by
binding to X11, BP1, ShcA and other adaptor proteins which
might link it to calcium signaling pathways (LaFerla, 2002) and
regulate the expression of genes involved in calcium homeostasis
such as S100a9 (Leissring et al., 2002; Pardossi-Piquard and
Checler, 2012).
Effect on Survival/Apoptosis Signaling
Pathways and Gene Expression
In severely compromised tissue, such as the ischemic core in
stroke, neurons undergo necrosis due to osmotic swelling, lack
of energy metabolites and breakdown of ion gradients (Lo
et al., 2003). Under milder and longer-lasting metabolic stress,
such as in the ischemic penumbra zone or in chronic cerebral
hypoperfusion, the balance between anti- and proapoptotic
pathways inclunding NF-κB and p53-pathways may tilt towards
apoptotic death (Dirnagl et al., 1999; Broughton et al., 2009).
In studies on cultured cells, APPsα was shown to exert
anti-apoptotic effects by mechanisms such as upregulation of
immediate early gene transcription factors, activation of CREB
and NF-κB, genes related to cell survival (Guo et al., 1998; Ryan
et al., 2013), phosphorylation of glycogen synthase kinase 3β
(GSK-3β; Jimenez et al., 2011) or regulation of expression of
cyclin-dependent kinase 5 (CDK-5; Hartl et al., 2013). Effects
may be mediated by binding of APPsα to several different
receptor proteins which are not yet unambiguously identified
(Gustafsen et al., 2013). Potential targets include membrane-
bound APP itself (Milosch et al., 2014), and direct inhibition
of BACE-1 by APPsα which would counteract Aβ-mediated
neurotoxicity (Obregon et al., 2012). Further protection of
amyloid toxicity by APPsα was mediated by increased expression
of the neuroprotective proteins transthyretin and insulin-like
growth factor 2 and subsequent inhibition of the proapoptotic
BAD (Stein et al., 2004). AICD was described to interact with
more than 20 adaptor proteins including Fe65 proteins members
of the Mint/X11 family and members of the JIP family (c-jun-N-
terminal kinase interacting protein, JIP1b and JIP2), translocate
to the nucleus and interact with survival-related genes (Pardossi-
Piquard and Checler, 2012).
Effects on Neurogenesis and Proliferation
Recent years have provided evidence for neurogenesis in several
regions of the adult human central nervous system including
the dentate gyrus, striatum and olfactory bulb. This mechanism
can, in principle, enhance cognitive functions and support
recovery from neuronal damage (Inta and Gass, 2015). APPsα
was found to stimulate proliferation of neuronal progenitor
cells in the subventricular zone (Caillé et al., 2004) and in the
hippocampus (Baratchi et al., 2012), whereas AICD was reported
to have antiproliferative effects (Zhou et al., 2011). An imbalance
between these APP products and thus between neurogenesis
and degeneration may contribute to the development of AD
(Zhou et al., 2011). Recently APP was shown to control adult
hippocampal neurogenesis through GABAergic interneurons,
regulating GABAergic synaptic transmission (Wang et al., 2014).
APP’s known trophic effects on neuronal viability, cell adhesion,
axonogenesis, dendritic arborization and dendritic spines may
also contribute to recovery from traumatic and metabolic insults
and counteract degeneration (Perez et al., 1997; Lee et al.,
2010). APPsα-mediated trophic effects are activity-dependent
and stimulated by activation of 5-HT4 and NMDAR (Gakhar-
Koppole et al., 2008; Cochet et al., 2013), suggesting them to be a
feasible adaptive strategy in LTP, plasticity and excitotoxicity.
POTENTIAL THERAPEUTIC STRATEGIES
Currently available pharmacological therapies in AD are mostly
based on acetylcholine esterase inhibitors such as donepezil and
rivastigmine or NMDAR blockers like memantine. They are far
from eliminating the (unknown) primary cause of the disease,
but do only alleviate symptoms and delay disease progression
(Huang and Mucke, 2012). Likewise, immunotherapeutic
approaches with antibodies against Aβ reduce amyloid burden,
but show only limited success in the prevention of cognitive
decline in ongoing phase III clinical trials (Reiman, 2016). One
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FIGURE 3 | Potential therapeutical interventions targeting APP
metabolites and its binding partners. Several strategies picking up on
involvement of APP and its metabolites in pathophysiological mechanisms
following acute insults are briefly portrayed. Depiction as a scale emphasizes
the importance of balanced APP metabolism. Therapeutical strategies may
employ either enhancement of neuroprotective action of APPsα such as block
of LTCC and NMDAR or elevation of APPsα levels by activation of
α-secretases or exogenous application. Other approaches might aim at
mitigating harmful effects of amyloid ß either by inhibition of its production,
prevention of deposition into plaques or facilitated degradation. These
strategies might ameliorate acute damage as well as prevent further
degeneration.
reason for the slow and tedious progress in therapy of AD
may be that cognitive deficits in AD arise not only due to
an excess of toxic metabolites, but also from loss of function
of protective APP products. Likewise, the past two decades of
research on neuroprotective strategies in ischemic stroke and TBI
have been hampered by failures to translate results from bench to
bedside (Hoyte et al., 2004; O’Collins et al., 2006). Mechanistic
understanding of APP’s role in these diseases may help to
break this streak. Restitution of the perturbed balance between
harmful and beneficial APP metabolites emerges as a promising
neuroprotective strategy. Although the hope to find a ‘‘cure for
all’’ seems delusive, shared pathological mechanisms in ischemia,
injury and AD imply that discovery of common leverage points
for novel drugs may be feasible. We will briefly discuss such
potential therapeutic strategies which may comprise activation
of α-secretases, inhibition of ß- and γ-secretases, exogenous
administration of APPsα or amyloid antibodies, control of
cellular calcium levels by block of LTCC and NMDAR, activation
of neuroprotective mechanisms and inhibition of proapoptotic
downstream targets of APP (Figure 3; Selkoe, 2011).
Activation of α-Secretases
A variety of potential strategies may shift the balance towards
non-amyloidogenic cleavage of APP, including modulation of
expression, trafficking and regulation of ADAM10 (Postina,
2012). Direct activation of α-secretases by etazolate has been
shown to be beneficial in TBI in mice (Siopi et al., 2013). As an
indirect mechanism, activation of muscarinic M1 acetylcholine
receptors has been reported to increase α-secretase cleavage
of APP and decrease Aß levels (Beach et al., 2001). Another
activator of α-secretase and inhibitor of β- und γ-secretase is
melatonin (Mukda et al., 2016). Increased dimerization of APP
via specific compounds such as disulfiram was shown to shift the
balance towards non-amyloidogenic cleavage products of APP
and thus may present a novel therapeutic approach (Libeu et al.,
2012). However, overexpression or activation of ADAM-10 may
also have harmful consequences due to effects on other substrates
of this enzyme (Clement et al., 2008).
Inhibition of β- and γ-Secretases
In mice, a selective γ-secretase inhibitor has already been
successfully tested, reaching a 33% reduction of Aβ levels
within 1 week, without causing severe side effects (Basi et al.,
2010). In a mouse model of TBI, pharmacological inhibition
of γ-secretase activity reduced post-traumatic tissue loss and
improved motor and cognitive recovery (Loane et al., 2009).
Both γ- and β-secretase process various other substrates than
APP, complicating the use of respective inhibitors (John et al.,
2003). However, strategies to specifically inhibit APP cleavage
by BACE-1 do exist (Ben Halima et al., 2016) and first BACE-1
inhibitors made it into clinical trials (Vassar et al., 2014).
Regulation of Calcium Homeostasis
Regulation of intracellular calcium is a promising
neuroprotective strategy (Duncan et al., 2010). As discussed
above, APP stabilizes calcium homeostasis by interacting with
LTCC, NMDAR and other signaling pathways, offering some
feasible pharmacological leverage points. LTCC blockers of the
dihydropyridine family such as the common antihypertensive
drugs nimodipine and nifedipine attenuate progression of
dementia in humans, inhibit Aβ formation in cell culture (Lovell
et al., 2015), counteract Aβ-mediated calcium increase and
excitotoxicity (Anekonda and Quinn, 2011) and alleviate Aβ-
related memory deficits in animal models (Gholamipour-Badie
et al., 2013). The NMDAR blocker memantine is not only an
established drug for treatment of AD (Danysz and Parsons,
2012), but has also protective effects against excitotoxicity in
small doses, being potentially beneficial in patients with high
risk of ischemic stroke (Trotman et al., 2015). Other potential
calcium-stabilizing approaches target downstream pathways of
AICD (Nagase and Nakayama, 2014).
Delivery of Exogenous APPsα
As proven in rodent models of TBI, intraventricular application
of exogenous APPsα or its heparin binding domain promote
neuronal survival and improve functional outcome (Corrigan
et al., 2014). Following TBI or malignant stroke, patients
often receive a decompressive craniotomy including ventricular
drainage or insertion of an intracranial pressure probe.
Application of APPsα through these entries seems feasible.
However, these results are highly preliminary and it remains to be
proven whether this technique is safe, beneficial and technically
feasible in human patients.
CONCLUSION
The immense multitude and complexity of APP interactions and
functions discovered in recent decades may seem overwhelming
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and evoke the concern to miss the forest for the trees.
Nevertheless, some common principles have emerged from
recent studies. APP is more than the mother molecule of
amyloid, and AD is more than an amyloido-tauopathy. In
this review article, we present convergent evidence from
human studies, animal models and in vitro experiments
for a neuroprotective role of APP in ischemia, brain injury
and neurodegeneration. Most studies suggest that these
neuroprotective and trophic effects are mainly conducted
by the extracellularly secreted fragment APPsα, whereas
amyloidogenic cleavage leads to various harmful consequences.
We hypothesize that under pathological conditions the cleavage
balance of APP is disturbed, and loss of its neuroprotective
function may contribute to disease development. While the
pathological role of APP in AD may result from an overshoot
of pathological products of APP (Aß), production of the
neuroprotective soluble fragment APPsα may, in turn, reflect
the normal, beneficial reaction of the organism to metabolic
challenges. Therefore shifting this balance towards APPsα
secretion may be a promising treatment strategy in AD, stroke
and TBI. Causal treatments are urgently needed in these
conditions. Novel therapeutic targets arise from unraveling
the mechanisms of APP-mediated neuroprotection such as
regulation of cellular calcium levels by LTCC and NMDAR
inhibition, regulation of survival and apoptosis signaling
pathways, trophic effects on synapto- and neurogenesis, synaptic
function, plasticity and memory formation. However, current
understanding of these highly complex processes and the specific
contributions of APP is far from complete, and successful
translation into clinic is still a major challenge. One of the
reasons might be the predominant focus on histopathological
endpoints in most studies in the field, largely neglecting
longitudinal functional studies. Deeper comprehension of
APP-related processes in living tissue, employing functional
electrophysiological and imaging techniques should complement
morphological studies. Combined (interventional) functional
and structural evidence may help to develop new neuroprotective
therapies.
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